RICE-ibrutinib in Relapsed DLBCL

• Status: Recruiting
• Trial end date: 2023-08-01

Summary

This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.

• Phase: Phase 2

Details

• Lead Sponsor: Singapore General Hospital
• Collaborator: Janssen, LP